menu

Licensing Opportunity

Our lead therapeutic program, NJA-730, is novel oligonucleotide drug that offers compelling licensing opportunities. The drug candidate has completed dosing of all subjects in its Phase 1 study in Australia, with no reporting of dose-limiting toxicities or other noteworthy findings at any evaluated doses, and NapaJen intends to initiate a proof-of-concept Phase 2 clinical trial of NJA-730 in acute GvHD in 2021 in both United States and Australia.

 

Contact NapaJen to Discuss Partnering Opportunities

If you are interested in exploring a collaboration or licensing opportunity with NapaJen, please contact:

Kazuhiro Kawauchi
Business Development Dept.
e-mail: info@napajen.com
e-mail: k.kawauchi@napajen.com
Phone: +81-42-316-6773
cell: +81-70-2493-1146